GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Retained Earnings

H. Lundbeck AS (LTS:0ND5) Retained Earnings : kr20,154 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. H. Lundbeck AS's retained earnings for the quarter that ended in Mar. 2024 was kr20,154 Mil.

H. Lundbeck AS's quarterly retained earnings increased from Sep. 2023 (kr19,753 Mil) to Dec. 2023 (kr19,877 Mil) and increased from Dec. 2023 (kr19,877 Mil) to Mar. 2024 (kr20,154 Mil).

H. Lundbeck AS's annual retained earnings increased from Dec. 2021 (kr16,571 Mil) to Dec. 2022 (kr18,189 Mil) and increased from Dec. 2022 (kr18,189 Mil) to Dec. 2023 (kr19,877 Mil).


H. Lundbeck AS Retained Earnings Historical Data

The historical data trend for H. Lundbeck AS's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Retained Earnings Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,979.00 15,748.00 16,571.00 18,189.00 19,877.00

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18,458.00 19,069.00 19,753.00 19,877.00 20,154.00

H. Lundbeck AS Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


H. Lundbeck AS  (LTS:0ND5) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


H. Lundbeck AS (LTS:0ND5) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines